Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Sotagliflozin: A Potential Test Of Patient-Physician Decision-Making

Jan 23 2019

• By Derrick Gingery

Diabetes-Concept_56048224_1200x675

Related Content

Sanofi In Pole Position In Oral Type 1 Diabetes With Zynquista Filings

May 24 2018

Sanofi's Sotagliflozin: Risk Of Ketoacidosis Divides US FDA Advisory Committee

Jan 18 2019

Sanofi's Oral Type 1 Diabetes Drug Approval May Hinge On Ketoacidosis Management

Jan 15 2019

SGLT2 Inhibitors' Warning On Ketoacidosis Recommends Drug Holidays

Dec 04 2015

Related Companies

Sanofi

Lexicon Pharmaceuticals, Inc.

Additional Topics

United States Advisory Committees Drug Approval Standards Regulation FDA Drug Review Metabolic Disorders BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window